Minimal residual disease in acute lymphoblastic leukemia: A new concept of complete remission;Leucemia mínima residual: Nuevo concepto de remisión completa

Anales de Pediatria

Volumn 63, Issue 5, 2005, Pages 390-395

  Bastida Vila P ^a   Palacio Garcia C ^b   Solsona Riera, M ^b   Ortega Aramburu, J J ^a   Sanchez De Toledo Codina J ^c  

^a HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c NONE

Author keywords

Acute lymphoblastic leukemia; Complete remission; Flow cytometry; Minimal residual disease

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; BONE MARROW BIOPSY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOLOGICAL TECHNIQUE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PROGNOSIS; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 29844432879     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13080401     Document Type: Article

References (21)

1. Conter V, Aricó M, Valsecchi MG, Basso G, Biondi A, Madon E, et al. Long term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukaemia studies, 1982-1995. Leukemia. 2000;14:2196-204.
2. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukaemia: 1983-1995. Leukemia. 2000;14:2223-33.
3. Schappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Heure G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 2000;14: 2205-22.
4. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A, et al. Long term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukaemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000;14:2257-66.
5. Ortega JJ, Ribera JM, Oriol A, Bastida P, González ME, Calvo C, et al. on behalf of PETHEMA Group. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Haematologica. 2001;86:586-95.
6. Béné MC, Castoldi GL, Knapp W on behalf of EGIL. Proposals for the immunological classification of leukaemias. Leukemia. 1995;9:1783-6.
7. Ross ME, Xiaodong Z, Song G, Shurtleff SA, Girlman K, Williams WK, et al. Classification of pediatric acute lymphoblastic leukaemia by gene expression profiling. Blood. 2003;102: 2951-9.
8. Ortega JJ. Leucemias agudas en niños. En: Sans Sabrafen, editor. Hematologia Clínica. 2000;366-78.
9. Tomás JF, Román A, Subirá D, Vizcarra E, Llamas P, Fernández de Velasco J. Enfermedad mínima residual. Significado de la remisión en enfermedades oncohematológicas. Haematologica (ed. esp.). 2004;89:50-6.
10. Vidriales MB, Pérez JJ, López-Berges MC, Gutiérrez N, Ciudad J, Lucio P, et al. Minmal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003;101:4695-700.
11. Van Dongen JJM, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-8.
12. Willemse MJ, Seriu T, Hettinger K, D'Aniello E, Hop WC, Panzer-Grümayer ER, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood. 2002;99:4386-93.
13. Coustan-Smith E, Behm FG, Sánchez J, Boyett JM, Hancock ML, Raimondi SC, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550-4.
14. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm SC, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691-6.
15. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:783-5.
16. Dworzak MN, Fröschi G, Printz D, Mann G, Pötschger U, Mühlegger N, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99:1952-8.
17. Björklund E, Mazur J, Söderhall S, Porwit-MacDonald. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia. 2003;17:138-48.
18. Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, William CL, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group Study. Leukemia. 2003;17:1566-72.
19. Marshall GM, Haber M, Kwan E, Zhu L, Ferrara D, Xue C, et al. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21:704-9.
20. Aricó M, Conter V, Valsecchi MG, Masera G. Importance of minimal residual disease testing during the scond year of disease: Still no answer? J Clin Oncol. 2003;21:4463-8.
21. Neale GAM, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH, et al. Comparative análisis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in hildhood acute lymphoblastic leukemia. Leukemia. 2004;18:934-8.